基因多态性与卵巢癌患者化疗疗效及预后的关系  

Relationship between the genetic polymorphism and the efficacy of chemotherapy and prognosis in patients with ovarian cancer

作　　者：王瑛 于娟 陈鹏[2] 张建好[3] WANG Ying;YU Juan;CHEN Peng;ZHANG Jianhao(Department of Gynecology and Obstetrics, Zhengzhou First People’s Hospital, Zhengzhou 450000, He’nan, China;Department of Clinical Laboratory, Zhengzhou First People’s Hospital, Zhengzhou 450000, He’nan, China;Department of Interventional Therapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, He’nan, China)

机构地区：[1]郑州市第一人民医院妇产科,郑州450000 [2]郑州市第一人民医院检验科,郑州450000 [3]郑州大学第一附属医院介入科,郑州4500000

出　　处：《癌症进展》2019年第8期972-974,共3页Oncology Progress

摘　　要：目的探讨Ephrin A型受体4(EPHA4)基因多态性与卵巢癌患者化疗疗效及预后的关系。方法采用基因测序法检测146例卵巢癌患者rs17348202位点EPHA4基因的多态性;评价患者的临床疗效;随访0～48个月,观察不同基因型卵巢癌患者的生存情况。结果 146例卵巢癌患者中,CC基因型患者20例,CT基因型患者57例,TT基因型患者69例。不同基因型卵巢癌患者的年龄、肿瘤直径、病理类型比较,差异均无统计学意义(P>0.05);TT基因型患者的化疗缓解率高于CC基因型和CT基因型患者(P<0.05);TT基因型患者的中位无疾病进展生存期(PFS)长于CC基因型和CT基因型患者(P<0.05)。结论 rs17348202位点EPHA4基因的多态性与紫杉醇对卵巢癌患者的化疗疗效有一定的关系,其对预测紫杉醇对卵巢癌患者的化疗效果可能具有一定的参考价值。Objective To investigate the relationship between the genetic polymorphism of Ephrin A type receptor 4 (EPHA4) and the efficacy of chemotherapy as well as the prognosis in patients with ovarian cancer. Method A total of 146 patients with ovarian cancer were included in the study, who were detected for the genetic polymorphism of EPHA4- rs17348202;the clinical efficacy of chemotherapy in these patients were evaluated;after 0~48 months of follow-up, the survival of patients with different genotypes were observed. Result In 146 patients of ovarian cancer, CC genotype was observed in 20 patients, CT genotype in 57 patients, and TT genotype in 69 patients;there was no significant difference in age, lesion diameter, pathological types and chemotherapy regimens among patients with above genotypes (P>0.05);while higher response rate of chemotherapy was noted in TT genotype compared with that of CC and CT genotype patients (P<0.05);besides, the median progression-free survival (PFS) of patients with TT genotype was also longer than that in those with CC or CT genotypes (P<0.05). Conclusion The genetic polymorphism of EPHA4-rs17348202 is reasonably associated with the efficacy of paclitaxel chemotherapy in ovarian cancer patients, thus it may be useful in predicting the efficacy of paclitaxel chemotherapy for ovarian cancer.

关 键 词：EphrinA型受体4 多态性 卵巢癌 紫杉醇 疗效 

分 类 号：R737.31[医药卫生—肿瘤]